Castle Hook Partners’s AstraZeneca AZN Stock Holding History

Castle Hook Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,967	Closed	-$1.77M	–	74
2026 Q1	$1.77M	Buy	8,967 +4,850	+118%	+$935K	0.01%	44
2025 Q4	$757K	Buy	+4,117	New	+$722K	﹤0.01%	58

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Castle Hook Partners's AZN Position: Q2 2026 in Review

Castle Hook Partners sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 8,967 shares — an estimated $1.77M sold.

Castle Hook Partners first reported a position in AZN in Q4 2025 and held it in 2 quarters. The position peaked at $1.77M in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Castle Hook Partners reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Castle Hook Partners sold 8,967 AstraZeneca shares in Q2 2026, an estimated $1.77M.
Castle Hook Partners first reported a position in AstraZeneca in Q4 2025 and held it in 2 quarters.
Castle Hook Partners's AstraZeneca position peaked at $1.77M in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Castle Hook Partners's 13F filing for Q2 2026, filed 14 Aug 2026.